Bioequivalence and Bioavailability Forum

Dear John,

❝ Use the example output I posted originally, can you walk me through the above maze?

I don't see the G-matrix in your post. Need I glasses ?
Have also a look at this post.

❝ On another note (off topic but it's short so I might as well...) if you have a 2x2x2 crossover study carried out in 2 groups, would the following Proc GLM model statement be sufficient? The only one in the model statment which I have question on is PERIOD(GROUP).

❝

❝ MODEL &pk= GROUP SEQUENCE SUBJECT(GROUP*SEQUENCE) PERIOD(GROUP) TREATMENT GROUP*TREATMENT/SS1 SS3;

❝ RANDOM SUBJECT(GROUP*SEQUENCE)/TEST;

I would agree. But:
Barbara Davit (in a letter to one of my clients) additionally to your code requested the group-by-sequence interaction in the model.

---

Edit: See another thread – starting with this post. Helmut